GlassScriptPhysician profile
Clifford Solomon
NPI 1457350555
$6,871.22
in general payments reported to CMS, 2019-2025
38 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $159 · 2021: $753 · 2022: $2,554 · 2023: $192 · 2024: $143 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,062 · Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,062.29 |
| Food and Beverage | $1,055.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,471.02 | 2021-2025 | Unid_pass, Anteralign Spinal System With Titan Nanolock Surface Technology |
| Si-Bone, INC. | $1,597.50 | 2020-2025 | |
| Globus Medical, INC. | $939.57 | 2019 | |
| Cerapedics INC. | $369.49 | 2021 | |
| Orthofix Medical, INC. | $198.02 | 2019-2025 | Spinal-Stim |
| Alexion Pharmaceuticals, INC. | $133.80 | 2019-2025 | Ultomiris |
| Kuros Biosciences USA, INC | $133.29 | 2025 | Magnetos |
| Bioventus LLC | $113.85 | 2023-2025 | Bonescalpel & Sonicone (O.R.), Bonescalpel |
| Lilly USA, LLC | $60.91 | 2019-2024 | Reyvow, Emgality |
| Ucb, INC. | $54.74 | 2019-2023 | Briviact |
| Csl Behring | $54.73 | 2019-2024 | Kcentra |
| Lundbeck LLC | $53.40 | 2021-2025 | Vyepti |
| 4web, INC. | $49.92 | 2020 | |
| Kls-Martin L.P. | $49.68 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.57 | 2023-2025 | Hyqvia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $46.32 | 2022-2023 | |
| Amgen INC. | $39.32 | 2019-2025 | Uplizna |
| Longeviti Neuro Solutions INC | $38.03 | 2025 | Clearfit |
| Mimedx Group, INC. | $33.83 | 2024 | |
| Avanir Pharmaceuticals, INC. | $31.99 | 2019 | |
| Horizon Therapeutics Plc | $29.23 | 2023 | Uplizna |
| Vertos Medical, INC. | $24.36 | 2023 | Mild Device Kit |
| Solventum Corporation | $22.79 | 2024 | Activ.A.C. |
| Radius Health, INC. | $22.52 | 2022 | |
| Providence Medical Technology, INC. | $22.29 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $21.09 | 2019 | |
| Supreme Orthopedic Systems, LLC | $21.04 | 2024 | |
| Merck Sharp & Dohme LLC | $20.96 | 2022 | |
| Boston Scientific Corporation | $20.46 | 2019 | |
| Medtronic USA, INC. | $19.84 | 2019 | |
| Intrinsic Therapeutics | $19.31 | 2023 | Barricaid Acd (Annular Closure Device) |
| Ultragenyx Pharmaceutical INC. | $18.55 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.13 | 2019 | |
| Smith+Nephew, INC. | $14.29 | 2019 | |
| Neurocrine Biosciences, INC. | $13.91 | 2021 | |
| Spineology INC. | $12.75 | 2019 | |
| Pfizer INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.